|
 |
|
|||||||
|
|||||||||
© 2004 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Restoration of Sensation, Reduced Pain, and Improved Balance in Subjects With Diabetic Peripheral Neuropathy
A double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment
Joslin Center for Diabetes, Morton Plant Mease Healthcare, Clearwater, Florida
Address correspondence and reprint requests to Sara Myers, RN, Joslin Center for Diabetes, 455 Pinellas St., Clearwater, FL 33756. E-mail: sara.myers{at}baycare.org
OBJECTIVE—Diabetic peripheral neuropathy (DPN) has been thought to be progressive and irreversible. Recently, symptomatic reversal of DPN was reported after treatments with a near-infrared medical device, the Anodyne Therapy System (ATS). However, the study was not controlled nor was the investigator blinded. We initiated this study to determine whether treatments with the ATS would decrease pain and/or improve sensation diminished due to DPN under a sham-controlled, double-blind protocol.
RESEARCH DESIGN AND METHODS—Tests involved the use of the 5.07 and 6.65 Semmes Weinstein monofilament (SWM) and a modified Michigan Neuropathy Screening Instrument (MNSI). Twenty-seven patients, nine of whom were insensitive to the 6.65 SWM and 18 who were sensitive to this filament but insensitive to the 5.07 SWM, were studied. Each lower extremity was treated for 2 weeks with sham or active ATS, and then both received active treatments for an additional 2 weeks.
RESULTS—The group of 18 patients who could sense the 6.65 SWM but were insensitive to the 5.07 SWM at baseline obtained a significant decrease in the number of sites insensate after both 6 and 12 active treatments (P < 0.02 and 0.001). Sham treatments did not improve sensitivity to the SWM, but subsequent active treatments did (P < 0.002). The MNSI measures of neuropathic symptoms decreased significantly (from 4.7 to 3.1; P < 0.001). Pain reported on the 10-point visual analog scale decreased progressively from 4.2 at entry to 3.2 after 6 treatments and to 2.3 after 12 treatments (both P < 0.03). At entry, 90% of subjects reported substantial balance impairment; after treatment, this decreased to 17%. However, among the group of nine patients with greater sensory impairment measured by insensitivity to the 6.65 SWM at baseline, improvements in sensation, neuropathic symptoms, and pain reduction were not significant.
CONCLUSIONS—ATS treatments improve sensation in the feet of subjects with DPN, improve balance, and reduce pain.
Abbreviations: ATS, Anodyne Therapy System • DPN, diabetic peripheral neuropathy • LOPS, loss of protective sensation • MNSI, Michigan Neuropathy Screening Instrument • SWM, Semmes Weinstein monofilament • VAS, visual analog scale
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. Lavery, D. P. Murdoch, J. Williams, and D. C. Lavery Does Anodyne Light Therapy Improve Peripheral Neuropathy in Diabetes?: A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy Diabetes Care, February 1, 2008; 31(2): 316 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Cornblath, A. Vinik, E. Feldman, R. Freeman, and A. J.M. Boulton Surgical Decompression for Diabetic Sensorimotor Polyneuropathy Diabetes Care, February 1, 2007; 30(2): 421 - 422. [Full Text] [PDF]
|
|
|
|
 |
|
 S. W Shaffer and A. L Harrison Aging of the Somatosensory System: A Translational Perspective Physical Therapy, February 1, 2007; 87(2): 193 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Burke The Effect of Monochromatic Infrared Energy on Sensation in Subjects With Diabetic Peripheral Neuropathy: A Double-Blind, Placebo-Controlled Study: Response to Clifft et al. Diabetes Care, May 1, 2006; 29(5): 1186 - 1186. [Full Text] [PDF]
|
|
|
|
|
|
J. K. Clifft, R. J. Kasser, T. S. Newton, and A. J. Bush The Effect of Monochromatic Infrared Energy on Sensation in Subjects With Diabetic Peripheral Neuropathy: A Double-Blind, Placebo-Controlled Study: Response to Burke Diabetes Care, May 1, 2006; 29(5): 1186 - 1187. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Heubeck New Treatment Options for Diabetic Neuropathy DOC News, February 1, 2006; 3(2): 8 - 9. [Full Text]
|
|
|
|
 |
|
 M. W. Powell, D. H. Carnegie, and T. J. Burke Reversal of diabetic peripheral neuropathy with phototherapy (MIRETM) decreases falls and the fear of falling and improves activities of daily living in seniors Age Ageing, January 1, 2006; 35(1): 11 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Clifft, R. J. Kasser, T. S. Newton, and A. J. Bush The Effect of Monochromatic Infrared Energy on Sensation in Patients With Diabetic Peripheral Neuropathy: A double-blind, placebo-controlled study Diabetes Care, December 1, 2005; 28(12): 2896 - 2900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Corbett Practical Management of Patients With Painful Diabetic Neuropathy The Diabetes Educator, July 1, 2005; 31(4): 523 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. DeLellis, D. H. Carnegie, and T. J. Burke Improved Sensitivity in Patients with Peripheral Neuropathy: Effects of Monochromatic Infrared Photo Energy J Am Podiatr Med Assoc, March 1, 2005; 95(2): 143 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J.M. Boulton Management of Diabetic Peripheral Neuropathy Clin. Diabetes, January 1, 2005; 23(1): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ziegler Polyneuropathy in the diabetic patient--update on pathogenesis and management Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2170 - 2175. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |